Tag - biogen

 
Menu
Search
 
November 22, 2024
 

Today's print edition

Home Delivery
Subscribe for more access

BIOGEN

Lecanemab was developed by drugmakers Eisai of Japan and Biogen of the United States.
JAPAN / Science & Health
Nov 15, 2024
European agency switches to recommending new Alzheimer's drug
The committee judged that the efficacy of lecanemab outweighs the risk for some patients.
A scientist looks at brain scans of a patient suffering from Alzheimer's disease in Geneva in 2023.
WORLD / Science & Health
Sep 21, 2024
Revolution or mirage? Controversy surrounds new Alzheimer's drugs
For defenders, the drugs represent a real chance to fight the disease. For detractors, they are a disappointment after a long line of costly failures.
Tests for patients suffering from Alzheimer's disease. According to the Alzheimer's Association, the disease is estimated to affect more than 6 million Americans.
WORLD / Science & Health / FOCUS
Apr 24, 2024
Alzheimer's drug adoption in U.S. slowed by doctors' skepticism
There is an entrenched belief among some doctors that treating the memory-robbing disease is futile.
Japan Times
WORLD / Science & Health
Jun 19, 2023
New Eisai and Biogen Alzheimer drug faces hurdles in Europe
Some doctors said its effect on the disease may not be clinically meaningful enough when weighed against the risk of brain swelling, its likely high price.
Japan Times
JAPAN
Jan 30, 2023
Priority review status given to Alzheimer's drug developed by Eisai and Biogen
The companies said priority review in Japan is granted to new medicines recognized as having high medical utility for serious diseases.
Japan Times
JAPAN / Science & Health
Dec 22, 2022
Japan approves blood test to detect Alzheimer’s
Japan has approved one of the world’s first blood test kits to detect signs of Alzheimer’s disease, paving way for a simpler and speedier diagnosis of the ailment for which a therapy is on the horizon.
Japan Times
BUSINESS
Nov 30, 2022
Eisai Alzheimer’s drug sparks debate over benefits as risks like brain bleeding emerge
The key issue is whether the modest slowing of the disease is meaningful to individual patients and their families, especially in light of the potential side effects.
Japan Times
BUSINESS / Markets
Nov 29, 2022
Eisai and Biogen plunge after report of second death in Alzheimer’s trial
The case involved a 65-year-old woman who died of a massive brain hemorrhage after suffering a stroke and a type of brain swelling and bleeding in an Eisai trial, a report said.
Japan Times
COMMENTARY / World
Oct 4, 2022
New Alzheimer's drug from Biogen and Eisai is just the beginning
A successful late-stage trial of lecanemab gives researchers promising new avenues for tackling this hard-to-beat disease.
Japan Times
WORLD / Science & Health / ANALYSIS
Sep 30, 2022
Eisai drug's trial success raises hope for Alzheimer's prevention
Scientists have already begun to debate whether the benefit of the drug is robust enough, but to many researchers, the findings suggest that preventing decline altogether is possible.
Japan Times
JAPAN / Science & Health
Sep 28, 2022
Alzheimer’s progression slowed by drug in major trial
The drug slowed cognitive decline in people with early Alzheimer's by 27% over 18 months when compared with a placebo using a common rating scale.
Japan Times
BUSINESS / Companies
Jul 6, 2022
Eisai says Alzheimer’s drug will get priority review in U.S.
Under the accelerated approval pathway, drugs can be approved based on their ability to remove amyloid, a hallmark of the disease, from the brain.
Japan Times
BUSINESS
Apr 9, 2022
Japan's Eisai still seeking accelerated U.S. review of Alzheimer's drug
The firm said it plans to seek a quick approval even after the Medicare health plan decided to limit coverage of medicines approved in that manner.
Japan Times
WORLD / Science & Health
Jan 12, 2022
Biogen stung as U.S. limits coverage of Alzheimer’s therapy
Private insurers in the U.S. have mostly declined to cover Aduhelm, saying they need more proof of its efficacy and that benefits outweigh risks like brain swelling.
Japan Times
WORLD
Sep 3, 2021
Lawmakers probe ‘anomalies’ in approval of Biogen Alzheimer’s drug
The congressional inquiry adds to pressure on the U.S. agency charged with regulating products that account for one-fifth of consumer spending.
Japan Times
WORLD / Science & Health
Jul 29, 2021
Doctors blast Biogen Alzheimer approval as ‘regulatory failure’
The New England Journal of Medicine opinion piece is another sign of persistent furor over the agency's decision.
Japan Times
COMMENTARY / World
Jul 19, 2021
Latest U.S. Alzheimer's drug fix is a patch job
Most of the FDA's decisions don't receive national attention, which means they may not be rectified until substantial harm is done.
Japan Times
COMMENTARY / World
Jun 14, 2021
Alzheimer’s drug furor highlights U.S. health system’s failures
The FDA didn't deny that the clinical-trial evidence was poor. It simply ignored that problem and used different reasoning to grant the drug 'accelerated approval.”
Japan Times
WORLD / Science & Health / ANALYSIS
Jun 11, 2021
U.S. FDA faces mounting criticism over Alzheimer's drug approval
The drug was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows progression of the disease.
Two of America’s biggest debt holders are dumping Treasurys
The U.S. Treasury building in Washington. Investors in Japan and China sold a pile of U.S. debt in the last quarter, just before the U.S. presidential election.
Ishiba aggravates his own political failures with diplomatic faux pas
Prime Minster Shigeru Ishiba is greeted at the APEC summit in Lima by Canadian Prime Minister Justin Trudeau on Friday. The Japanese leader was criticized for remaining seated while meeting several world leaders at the event.
Japan's 3.31 million visitors in October set monthly record
Kiyomizu Temple in Kyoto in December 2023. Famous autumn leaf colors contributed to increased tourism demand last month from many markets across Asia, Europe and North America, the Japan National Tourism Organization has said.
Japan ranks last in romance satisfaction for second straight year
In a survey of 31 countries, Japan ranked last in terms of those who felt loved, with just 51% of respondents saying so.
Ruling coalition and DPP strike last-minute deal over economic policy
DPP policy chief Makoto Mahaguchi speaks at the party's policy gathering in Tokyo on Wednesday.
Japan, U.K. and Italy discuss inviting more countries to joint fighter project
A new concept model of a next-generation fighter jet to be jointly developed by Japan, Britain and Italy is on display in Farnborough, Hampshire, in July.
Haruki Murakami's 'The City and Its Uncertain Walls' gives deep deja vu
For “The City and Its Uncertain Walls,” translated into English by Philip Gabriel, Haruki Murakami confronts the ghosts who won't leave him alone.
Japanese expats in Asia find community through rugby
The Taiwan Fivewoods celebrate their victory at the 2023 Asian Japanese Rugby Cup in December of last year.
In Fukushima, a weekend of prose, poetry and translation
Aomori-based writer JJ Carter presented on tabletop gaming as creative inspiration for building characters and narratives.
For Dr. Nakamats, aging is just experience in action
Though he didn't win the recent gubernatorial election in Tokyo, the 96-year-old Dr. Nakamats' run was seen as inspirational in Japan's aging society.

Podcast

One of the many entrances to the Kabukicho neighborhood in Tokyo’s Shinjuku Ward.
Kabukicho: Tokyo’s ‘stadium of desire’

Longform

Construction takes place on the Takanawa Gateway Convention Center in Tokyo, slated to open in 2025.
A boom for business tourism in Japan?
By Kathryn Wortley

SUSTAINABLE JAPAN

mission sustainability vol.12 : Kose Corp.Kose takes pride in creating beauty in the world
mission sustainability vol.12 : Kose Corp.Kose takes pride in creating beauty in the world

SPECIAL SUPPLEMENTS note

Read more

SUPPLEMENTS BINDER